Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 in seasonal allergic rhinitis
NCT06171074Phase 2Not yet recruiting
- Sponsor
- Keymed Biosciences
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of stapokibart in seasonal allergic rhinitis (SAR), sponsored by Keymed Biosciences. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
stapokibart
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT06171074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06171074.